A cost comparison of benralizumab, mepolizumab, and dupilumab in patients with severe asthma: A US third-party payer perspective

Incremental net monetary benefit of biologic therapies in moderate to severe asthma: a systematic review and meta-analysis of economic evaluation studies

(2023) Sajesh K. Veettil et al.   JOURNAL OF ASTHMA

Assessing Construct Validity of the Asthma Impairment and Risk Questionnaire Using a 3-month Exacerbation Recall

(2022) Bradley E. Chipps et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Biologic Therapies for Severe Asthma

(2022) Guy G. Brusselle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Real-world effectiveness of benralizumab: Results from the ZEPHYR 1 Study

(2022) Yen Chung et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis

(2022) Ayobami Akenroye et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

COST-EFFECTIVENESS OF BENRALIZUMAB VERSUS MEPOLIZUMAB AND DUPILUMAB IN PATIENTS WITH SEVERE UNCONTROLLED EOSINOPHILIC ASTHMA IN SPAIN

(2022) M Mareque et al.   JOURNAL OF ASTHMA

Clinical and economic burden of severe asthma among US patients treated with biologic therapies

(2021) Joan Reibman et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Eosinophilic and non-eosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort

(2021) Liam G. Heaney et al.   CHEST

Severe asthma exacerbations in the United States:

(2021) Jennifer Trevor et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study)

(2021) Wendy C. Moore et al.   EUROPEAN RESPIRATORY JOURNAL

Integrated Safety and Efficacy Among Patients Receiving Benralizumab for Up to Five Years

(2021) Stephanie Korn et al.   Journal of Allergy and Clinical Immunology-In Practice

Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study

(2021) Andrew Menzies-Gow et al.   Lancet Respiratory Medicine

Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study

(2021) Michael E Wechsler et al.   Lancet Respiratory Medicine

Severe asthma: oral corticosteroid alternatives and the need for optimal referral pathways

(2020) Didier Cataldo et al.   JOURNAL OF ASTHMA

Oral Corticosteroid Treatment Patterns of Patients in the United States with Persistent Asthma

(2020) Trung N. Tran et al.   Journal of Allergy and Clinical Immunology-In Practice

Systemic Corticosteroid-Related Complications and Costs in Adults with Persistent Asthma

(2020) Robert Zeiger et al.   Journal of Allergy and Clinical Immunology-In Practice

Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial

(2020) Tim W Harrison et al.   Lancet Respiratory Medicine

The Projected Economic and Health Burden of Uncontrolled Asthma in the United States

(2019) Mohsen Yaghoubi et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Phenotypes and endotypes of adult asthma: Moving toward precision medicine

(2019) Ravdeep Kaur et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Systematic Literature Review of Systemic Corticosteroid Use for Asthma Management

(2019) Eugene R Bleecker et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: the COSMEX Study

(2019) Sandhya Khurana et al.   CLINICAL THERAPEUTICS

Severe Eosinophilic Asthma

(2019) Bakakos et al.   Journal of Clinical Medicine

Eosinophilic Asthma

(2019) Ryan K. Nelson et al.   Journal of Allergy and Clinical Immunology-In Practice

Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma

(2018) William W. Busse et al.   ADVANCES IN THERAPY

Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma

(2018) Klaus F. Rabe et al.   NEW ENGLAND JOURNAL OF MEDICINE

Systematic literature review of the clinical, humanistic, and economic burden associated with asthma uncontrolled by GINA Steps 4 or 5 treatment

(2018) Stephanie Chen et al.   CURRENT MEDICAL RESEARCH AND OPINION

Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

(2017) Theo Vos et al.   LANCET

Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma

(2017) Parameswaran Nair et al.   NEW ENGLAND JOURNAL OF MEDICINE

Burden of Chronic Oral Corticosteroid Use by Adults with Persistent Asthma

(2017) Robert S. Zeiger et al.   Journal of Allergy and Clinical Immunology-In Practice

Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study

(2016) Njira Lugogo et al.   CLINICAL THERAPEUTICS

The global economic burden of asthma and chronic obstructive pulmonary disease

(2016) S. Ehteshami-Afshar et al.   INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE

Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial

(2016) Eugene R Bleecker et al.   LANCET

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

(2016) J Mark FitzGerald et al.   LANCET

Economic Burden of Illness Among Patients with Severe Asthma in a Managed Care Setting

(2016) Benjamin Chastek et al.   Journal of Managed Care & Specialty Pharmacy

Adrenal Insufficiency in Corticosteroids Use: Systematic Review and Meta-Analysis

(2015) Leonie H. A. Broersen et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma

(2014) Elisabeth H. Bel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma

(2014) Hector G. Ortega et al.   NEW ENGLAND JOURNAL OF MEDICINE

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

(2013) K. F. Chung et al.   EUROPEAN RESPIRATORY JOURNAL

The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use

(2009) Stephanie C. Manson et al.   RESPIRATORY MEDICINE

Economic burden of asthma: a systematic review

(2009) Katayoun Bahadori et al.   BMC Pulmonary Medicine

Overdiagnosis of asthma in obese and nonobese adults

(2008) S. D. Aaron et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL